Company profile: Noema Pharma
1.1 - Company Overview
Company description
- Provider of biotech therapies addressing disabling symptoms in orphan conditions of the brain and nervous system, with a pipeline including Phase 2b trials for childhood-onset fluency disorder (stuttering), tuberous sclerosis complex (seizures) and trigeminal neuralgia (severe pain), a Phase 2a trial in Tourette syndrome (involuntary tics), and a Phase 2-ready triple reuptake inhibitor for atypical depression and binge eating disorder.
Products and services
- Phase 2b Childhood Onset Fluency Disorder (COFD) trial: A clinical trial advancing a therapy targeting stuttering in children, addressing disabling speech disfluency in orphan brain and nervous system conditions
- Phase 2b Trigeminal Neuralgia (TN) trial: A clinical trial evaluating a therapy targeting severe pain associated with Trigeminal Neuralgia, addressing disabling nervous system symptoms and meeting patient needs
- Phase 2b Tuberous Sclerosis Complex (TSC) trial: A clinical trial progressing a treatment of seizures associated with TSC, focused on mitigating disabling brain-system symptoms in an orphan neurological condition
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Noema Pharma
MicroVention
HQ: United States
Website
- Description: Provider of catheter-based and minimally invasive neuroendovascular technologies for cerebral aneurysms and other neurovascular diseases, including delivery and detachment systems, access products, intraluminal devices, occlusion balloons, and flow diverters. Products include FRED X flow diverter, WEB Embolization System, BOBBY balloon guide catheters, and SOFIA Flow Plus aspiration catheter.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MicroVention company profile →
Mission Therapeutics
HQ: United Kingdom
Website
- Description: Provider of small-molecule therapeutics targeting deubiquitylating enzymes to enhance mitophagy and remove dysfunctional mitochondria for the treatment of cancer, acute kidney injury, and other diseases. Offerings include MTX325 (CNS-penetrant USP30 inhibitor), MTX652 (peripheral USP30 inhibitor), a proprietary DUB platform, and USP30 inhibitor programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mission Therapeutics company profile →
Cadent Therapeutics
HQ: United States
Website
- Description: Provider of novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease, leveraging a precision neuroscience approach combining target specificity, patient selection, and drug design and optimization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cadent Therapeutics company profile →
Aelis Farma
HQ: France
Website
- Description: Provider of signaling-specific therapeutics targeting GPCRs, notably the CB1 receptor, including AEF0117 for cannabis-related disorders, AEF0217 for cognitive deficits (initially Down syndrome, with potential for Fragile X syndrome and aging), and CB1-SSi inhibitors that selectively inhibit pathological CB1 hyperactivity without affecting normal brain functions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aelis Farma company profile →
Synergia Medical
HQ: Belgium
Website
- Description: Provider of optoelectronic neurostimulation devices and platforms, including NAO.VNS for drug-resistant epilepsy via Vagus Nerve Stimulation, and technologies such as non-metallic encapsulation, fast wireless charging, custom optical leads, and miniaturized photovoltaic cells to advance therapies for chronic pain, Parkinson’s disease, epilepsy, sleep apnea, and depression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synergia Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Noema Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Noema Pharma
2.2 - Growth funds investing in similar companies to Noema Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Noema Pharma
4.2 - Public trading comparable groups for Noema Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →